Tests tumor samples from people treated with a gene-modified cell therapy
Checks tumor samples for the therapy's genetic marker in people with a second cancer.
Plain-language title generated from the registry record
Registry title: Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Key facts
- Where
- Essen, GermanySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The service is looking for people who had a Bristol-Myers Squibb gene modified cell therapy and then developed a qualifying second primary cancer. Their tumor sample is tested for transgene levels.
- Sex
- All sexes can join.
- Disease stage
- A qualifying second primary malignancy, or a second primary malignancy which BMS has qualified for testing.
- Earlier treatment
- Must have received a commercially available Bristol-Myers Squibb (BMS) manufactured gene modified cell therapy (GMCT), also in a clinical trial or other investigational setting with no testing protocol of its own.
Main reasons for not taking part
- Actively taking part in a clinical trial where information and samples are collected under that trial
- Has not received a BMS manufactured gene modified cell therapy
- Has not been diagnosed with a qualifying second primary malignancy
Read by machine on 12 November 2026.
Where in Germany
- Universitaetsklinikum Essen (AoR)Essen, GermanyContact: Bastian von Tresckow, Site 0001Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06357754
- Record updated
- 22 January 2026
- Original description
The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.Read full original descriptionShow less
Protocol for Transgene Assay Service
The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.
Inclusion: Participant has received a commercially available Bristol-Myers Squibb (BMS) manufactured Gene Modified Cell Therapy (GMCT) and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing; Participant has received a commercially available BMS manufactured GMCT in a clinical trial or other investigational setting (including non-conforming product) for which there is no testing protocol in place for that trial or investigational setting and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing.
Exclusion: Participant has not received a BMS manufactured GMCT or has not been diagnosed with a qualifying second primary malignancy; Participant is actively participating in a clinical trial where information and sample collection is being conducted under that clinical trial.